[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596595":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":10,"responsibleParty":16,"collaborators":10,"id":18,"slug":19,"hasResults":20,"nctId":21,"briefTitle":22,"officialTitle":23,"acronym":10,"eligibilityCriteria":24,"healthyVolunteers":20,"sex":25,"minAge":26,"maxAge":10,"enrollmentInfo":27,"targetDuration":10,"studyType":30,"phases":10,"briefSummary":31,"conditions":32,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":10},{"fullName":5,"class":6},"Boehringer Ingelheim","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Heart failure and preserved ejection fraction patients",null,[12],{"name":5,"role":13,"phone":14,"phoneExt":10,"email":15},"CONTACT","1-800-243-0127","clintriage.rdg@boehringer-ingelheim.com",{"type":17,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100596595","real-world-study-to-describe-the-effectiveness-and-safety-outcomes-of-jardiance-in-chinese-patients-with-heart-failure-and-preserved-ejection-fraction-100596595",false,"NCT07047508","Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction","A Non-interventional Study of the Effectiveness and Safety Outcomes in Patients With Heart Failure and Preserved Ejection Fraction (HFpEF) Initiating Jardiance in China: A Sub-study of the Post-marketing Study of Jardiance Among Patients With Heart Failure in China","Inclusion criteria:\n\n* At least 18 years of age\n* At least 6 months of data prior to the index date\n* Left ventricular ejection fraction (LVEF) \\> 40 %\n* N-terminal Pro-B-type natriuretic peptide (NT-proBNP) \\> 125 pg\u002FmL or brain natriuretic peptide (BNP) ≥ 35 pg\u002FmL\n* At least 1 diagnosis of Heart failure with preserved ejection fraction (HFpEF) or Heart failure with mid-range ejection fraction (HFmrEF) or chronic heart failure (CHF) at baseline during the look-back period (on or prior to the index date)\n* New users of Jardiance® (initiating Jardiance® on or after March 1st, 2023, and without any record of Jardiance® prescription during the look-back period)\n* Body Mass Index (BMI) \\\u003C45 kg\u002Fm2\n\nExclusion criteria:\n\n-Patients treated with any other sodium-glucose cotransporter-2 inhibitors (SGLT2i) on the index date or during the look-back period","ALL","18 Years",{"count":28,"type":29},3000,"ESTIMATED","OBSERVATIONAL","The main objective of the study is to describe the effectiveness and safety outcomes among Chinese hospitalized heart failure with preserved ejection fraction (HFpEF) patients initiating Jardiance® in the real-world setting.",[33,34],"Heart Failure","Preserved Ejection Fraction","NOT_YET_RECRUITING","2026-02-12",{"date":38,"type":39},"2026-02-13","ACTUAL",{"date":41,"type":29},"2028-01-31",{"date":43,"type":29},"2028-12-31",{"name":5,"class":6}]